Adrenal Metastases SBRT
This talk will discuss the role of stereotactic body radiotherapy (SBRT) in the treatment of adrenal metastases, focusing on clinical outcomes, toxicity, and patient selection. The potential integration of SBRT within the oligometastatic treatment paradigm will also be addressed. Register
Single Fraction SBRT for Oligometastases
Dr. Olson will present on the literature supporting single fraction SABR/SBRT, with a specific focus on oligometastases. He will highlight the rationale to pursue this treatment and current trials open to test it’s safety and effectiveness.
How to Integrate Systemic Therapy and SBRT in the Treatment of NSCLC Brain Metastases or Oligometastases
In this presentation given by an expert in radiotherapy and an expert in systemic therapy for lung cancer, the available data on systemic therapy and SBRT in the treatment of NSCLC brain metastases and oligometastases will be discussed. Focus will be on how to integrate these two and how to address current knowledge gaps.
SBRT for Non-Spine Bone Metastases – A Review of Recent Literature & Guidelines
This webinar will review recent publications on SBRT for NSBM and recent consensus guidelines, including technical aspects of radiation planning. We will discuss areas of uncertainty and variability in clinical practice.
SBRT for Oligometastatic Cancer, What’s New?
Stereotactic radiotherapy is commonly utilized as metastasis directed therapy, with the aim to optimize local control, progression free survival, and in some instances even overall survival. In this presentation, we will review the most up to date evidence in this space, while also highlighting higher-risk scenarios for toxicity.
Management of Oligometastatic Breast Cancer: Considerations for Local Therapy
Summary & Objectives: Review current literature surrounding local therapy in oligometastatic/progressive breast cancer Develop framework/scenarios to consider local therapy Dosing and systemic therapy considerations
Current Developments in the Field of Oligometastatic Disease
Oligometastatic disease has been described as an intermediate cancer stage by Hellman and Weichselbaum decades ago, and was based on mostly observational clinical data. Today, it has been recognized that oligometastatic disease represents a heterogeneous disease where the combination of local and systemic therapy aim for different clinical endpoints in different patient populations. The current […]
Genomic Biomarkers and Correlates of Outcome in Brain Metastases
The molecular underpinnings of brain metastasis are poorly characterized, but emerging data suggest genomic features unique to brain metastasis that could predict CNS tropism, CNS-specific outcomes following definitive local and systemic therapy, and which could be utilized for therapeutic selection. In this talk, we’ll review previously published and ongoing work by the Pike Lab and […]
SBRT for Oligometastases: Past, Present, Future.
This presentation will review the history of treating oligometastases with ablative therapy. It will discuss and interpret new evidence for and against the oligometastatic state, and provide some guidance for clinical practice. Finally, it will review some ongoing trials that are expected to inform clinical practice in the next few years.
Oligometastases To and From the Lung – the Role of SABR
Oligometastatic disease is one of the most topical areas in radiation oncology in the present era. Several key trials have embedded the use of stereotactic ablative body radiotherapy (SABR) in the modern oncological armamentarium. However there are several key considerations for routine clinical practice; these include the optimal dose, sequencing, safety, combinations with systemic therapy […]
Adaptive MR Guided Ablative RT for Abdominal Lymph Nodes
The feasibility of adaptive MR Guided RT using a 1.5 tesla MRL will be presented. Case examples will be reviewed, and questions regarding adaptive capabilities, and treatment approaches will be addressed.
A Comprehensive Review of The Role of Radiotherapy for Bone Metastases: When Do we use advanced techniques in era of new systemic agents?
The speaker will be discussing the evolving role of radiation therapy for bone metastases. A review of the literature will be presented with updates on trials for non-spine bone metastases. In addition, the audience will hear about clinical cases and parameters for treating patients with bone metastases.
Stereotactic Radiation and Hypofractionation in Gynecological Cancers
The objectives of this webinar are:
SBRT and Prostate Oligometastases
Dr. Patrick Cheung is a radiation oncologist at the Sunnybrook Odette Cancer Centre, University of Toronto, specializing in genito-urinary and lung malignancies, with a clinical and academic interest in using stereotactic body radiotherapy (SBRT) for oligometastatic and oligoprogressive cancer. In this webinar, he will talk about the role of metastasis directed therapy for oligometastatic prostate cancer. Discussion points […]
Stereotactic Radiotherapy for Oligometastatic Cancer: Expanding Reality
The incidence of oligometastatic cancer (low burden metastatic disease) is constantly growing due to the advancement in medical imaging and increase in primary cancer cure rates. Metastasectomy and other local modalities including stereotactic radiotherapy, termoablation, high intensity focus ultrasound (HIFU) etc. have been introduced in this particular clinical scenario. New terms like metastasis-directed therapy (MDT) […]
SBRT for Oligometastatic Disease
SBRT in oligometastatic patients is an extremely exciting topic, as it may represent a fantastic opportunity to improve cancer patients’ prognosis and also to possibly cure some of them. I will try to define who is the oligometastatic patient and I will show what evidence we currently have of local ablative approaches integrating the traditional […]